The future of
single-domain antibodies

Company overview

Since its inception in 1998, Hybrigenics has been a major player in the field of protein interactions with landmark contributions and achievements. Hybrigenics scientists were among the first to provide the community with high quality, large-scale protein interaction maps for bacteria (Rain et al. Nature 2001) and eukaryotes such as Drosophila (Formstecher et al., Genome Research 2005) and Homo sapiens (Colland et al., Genome Research 2004).

The company was founded on its optimized yeast two-hybrid (Y2H) technology that enables researchers to discover novel protein interactions in any cell type or tissue in a comprehensive manner. Our patented protocol is backed by unique bioinformatics capabilities for traceability, storage of experimental data and time-saving analysis and presentation of the results.

Our protein interaction platform was opened to the scientific community in 2003. Ever since, Hybrigenics has been the world leading provider of services to study protein interactions.

Hybribody is our new All-In-One service for the selection and validation of nanobodies® derived from a fully synthetic, proprietary humanized VHH antibody library. The single-chain VHH Abs (nanobodies) can be easily fused to a tag of your choice (ie. fluorescent markers, enzymes, multi-Fc species) resulting in fully-functional recombinant nanobodies for a wide-range of in vitro and in vivo applications (ELISA, IF…). You will find detailed information on the pages dedicated to Antibody Selection Technologies and our Hybribody services.

Researchers will benefit from our team's extensive experience in project management and design, construction and screening of high-quality expression libraries, bioinformatics support and analysis as well as functional interpretation of proteomic results. We conduct rigorous quality controls at every step of our process. Learn more about Hybrigenics Services history on our corporate website.

Hybribody technology has been developed in partnership with Dr Franck Perez’ lab at Curie Institute in Paris and funded by the National Research Agency (ANR, Agence Nationale pour la Recherche).


 Nanobody® is a registered trademark of Ablynx

Back to Top